Age, Biography and Wiki

Marc Lacroix (Marc Guy Albert Marie Lacroix) was born on 28 April, 1963 in Verviers, Belgium, is a Marc Guy Albert Marie Lacroix is biochemist. Discover Marc Lacroix's Biography, Age, Height, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is he in this year and how he spends money? Also learn how he earned most of networth at the age of 60 years old?

Popular As Marc Guy Albert Marie Lacroix
Occupation N/A
Age 60 years old
Zodiac Sign Taurus
Born 28 April, 1963
Birthday 28 April
Birthplace Verviers, Belgium
Nationality Belgium

We recommend you to check the complete list of Famous People born on 28 April. He is a member of famous with the age 60 years old group.

Marc Lacroix Height, Weight & Measurements

At 60 years old, Marc Lacroix height not available right now. We will update Marc Lacroix's Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.

Physical Status
Height Not Available
Weight Not Available
Body Measurements Not Available
Eye Color Not Available
Hair Color Not Available

Dating & Relationship status

He is currently single. He is not dating anyone. We don't have much information about He's past relationship and any previous engaged. According to our Database, He has no children.

Family
Parents Not Available
Wife Not Available
Sibling Not Available
Children Not Available

Marc Lacroix Net Worth

His net worth has been growing significantly in 2023-2024. So, how much is Marc Lacroix worth at the age of 60 years old? Marc Lacroix’s income source is mostly from being a successful . He is from Belgium. We have estimated Marc Lacroix's net worth, money, salary, income, and assets.

Net Worth in 2024 $1 Million - $5 Million
Salary in 2024 Under Review
Net Worth in 2023 Pending
Salary in 2023 Under Review
House Not Available
Cars Not Available
Source of Income

Marc Lacroix Social Network

Instagram
Linkedin
Twitter
Facebook
Wikipedia Marc Lacroix Wikipedia
Imdb

Timeline

1963

Marc Guy Albert Marie Lacroix (born 28 April 1963 in Verviers, Wallonia, Belgium) is a biochemist (educated at University of Liège) and a researcher who specializes in breast cancer biology, metastasis and therapy.

He works at Institut Jules Bordet (Brussels, Belgium).

He lives in Baelen

Breast cancer cells (BCC) frequently metastasize to the skeleton, where they lead to tumor-induced osteolysis and subsequent morbidity.

Marc Lacroix has investigated the interrelationships between BCC and bone cells (osteoblasts, the bone-building cells, and osteoclasts, the bone-degrading cells).

With colleagues, he discovered that BCC produce soluble factors increasing osteoclast activity, notably interleukin-11, the production of which is reduced by the cyclooxygenase inhibitor aspirin.

BCC also reduce the proliferation of osteoblasts and their production of collagen, the main protein component of bone.

Marc Lacroix also examined the response BCC to the anti-osteolytic agent calcitonin

In close collaboration with Prof. Guy Leclercq (Laboratoire Jean-Claude Heuson de Cancérologie Mammaire, Institut Jules Bordet, Belgium), Marc Lacroix has studied various aspects of estrogen receptor biology, ligand-binding and transcriptional activity, and life-cycle.

The amount of data on breast cancer available for the scientific and medical community is growing rapidly.

According to PubMed, a search engine offering access to the MEDLINE database of citations and abstracts of biomedical research articles, 7918 papers containing the expression «breast cancer» were published in 2006.

Their number was 3592 in 1996, 1455 in 1986 and only 626 in 1976.

In general, the older information is overlaid by more recent data and forgotten to some extent.

2004

In 2004, Lacroix and colleagues collected and assembled data from hundreds of articles related to the biology, pathology and genetics of in situ, invasive and metastatic breast cancers.

These papers were covering a time period of about 25 years.

Lacroix et al. concluded that despite undergoing increasing genetic alteration, most individual breast cancers rather surprisingly maintain their phenotype when they evolve from in situ to the metastatic state.

This conclusion was in opposition to a progression model widely accepted at that time, which was suggesting that carcinoma in situ could evolve into invasive carcinoma and subsequently produce metastases through an accumulation of molecular abnormalities possibly allowing extensive phenotype changes and subsequent gain of aggressiveness.

Over the years, Marc Lacroix has been refereeing for several international scientific and clinical journals: